Baxter won European CE mark approval to bring to the continent its PrisMax continuous renal replacement and organ support therapy system, as well as the TherMax blood warmer. The PrixMax is based on the company’s Prismaflex system, and is designed to make extracorporeal simpler, faster, and more accurate than before.
Along with specialty dialyzers, the PrisMax can deliver any kind of fluid therapy for kidney injury and sepsis management, including excess fluid removal and control of inflammatory mediators.
“Baxter has been a leader in continuous renal replacement therapy (CRRT) technology for more than 20 years. We’ve built on this expertise to bring to market the most advanced technology currently available that directly addresses what clinicians have said they need to better treat patients: simplicity, efficiency and accuracy,” in a published statements adi Reaz Rasul, general manager of Baxter’s Acute Therapies business. “The PrisMax system is foundational to accomplishing our shared vision to help transform care for critically ill patients and establish best-in-class treatments for a variety of organ support therapies.”
The newly approved TherMax blood warmer makes sure that the blood, having been treated, is returned to the patient’s body at the correct temperature. Features such as leak detection and close temperature control help make the whole package work together seamlessly in the ICU.